P275: Development and reliability of the new endoscopic virtual chromoendoscopy score: the PICaSSO score (the Paddington International Virtual ChromoendoScopy ScOre) in ulcerative colitisECCO '17 Barcelona
2017
P276: A snap-shot review of small bowel capsule endoscopy in the setting of inflammatory bowel diseaseECCO '17 Barcelona
2017
P277: Comparative accuracy of US versus MRI and colonoscopy in assessing disease activity and complications and influencing the decision-making process in Crohn's diseaseECCO '17 Barcelona
2017
P279: Children born to mothers with inflammatory bowel disease – Is there any risk for newborns' complication and development during the childhood?ECCO '17 Barcelona
2017
P280: Therapeutic drug monitoring of infliximab and adalimumab for detection of patients at risk of loss of response in inflammatory bowel diseaseECCO '17 Barcelona
2017
P281: Factors at diagnosis associated with disabling disease course in Crohn's diseaseECCO '17 Barcelona
2017
P282: Does colonoscopy alter the post-procedural fecal calprotectin results in Crohn's disease patients with ileocecal resection?ECCO '17 Barcelona
2017
P283: Quantum blue® adalimumab: development of the first point of care rapid test for therapeutic drug monitoring of serum adalimumab levelsECCO '17 Barcelona
2017
P285: Usefulness of a multidisciplinary approach combining both rheumatology and gastroenterology for the assessment and treatment of inflammatory bowel disease patientsECCO '17 Barcelona
2017
P286: Evaluation of fecal S100A12 in patients with inflammatory bowel diseaseECCO '17 Barcelona
2017
P287: Lipid peroxidation levels and antioxidant status in serum, plasma and saliva of patients with active and inactive Crohn's diseaseECCO '17 Barcelona
2017
P288: Treating beyond symptoms in inflammatory bowel disease (IBD): the Kent IBD Nurse Experience with the Steroid assessment toolECCO '17 Barcelona
2017
P289: Outcome of endoscopic ally resected dysplasic lesions in ulcerative colitisECCO '17 Barcelona
2017
P291: Proteinase 3-antineutrophil cytoplasmic antibodies (PR3-ANCA) would be a predictive biomarker for the clinical course of ulcerative colitisECCO '17 Barcelona
2017